Oxford BioMedica (LSE:OXB) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


LSE:OXB Oxford BioMedica PLC LSE:OXB
68 GF Score
Price £6.00
GF Value £5.35
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Oxford BioMedica's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LSE:OXB vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Oxford BioMedica's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Margin of Safety % (DCF Earnings Based) falls into.


LSE:OXB
68GF Score
Oxford BioMedica PLC LSE:OXB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of £6.00 is trading 12.1% above its estimated GF Value™ of £5.35. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for LSE:OXB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: £5.35 vs. price of £6.00 (12.1% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBDF:USAOXBl:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score

Get the complete analysis for LSE:OXB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£6.00
Price
£5.35
GF Value